Mirum Pharmaceuticals Inc (MIRM)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Mirum Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 25 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 104.60 $ — 69% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 25.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 25.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -43.4%
- ROCE > 15% -3.5%
- Expected return > 10% 26.2%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
7 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 89.1% passed
- More than 10% revenue growth is expected for the coming year 20.6% passed
- Share count grows by less than 3% a year 13.9% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 65.3% passed
- Gross margin at 40% or higher and without meaningful erosion 80.7% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 64 m net cash passed
- Operating cash flow covers the profits of the last three years 270 m passed
- Return on capital at 15% or higher, or up versus two years ago -3.5% failed
- Insiders hold at least 10% or are net buyers 1.4% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 40.1% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -14.24 | -14.24 – -14.24 | 675 | -2,929.8% | 1 |
| 12/31/2027 | -0.19 | -1.24 – 0.70 | 815 | 98.7% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.77 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.49 | – | 99 | 42.90 | -23.90 | -5 | -5 |
| 2025: Q1 | -0.30 | – | 112 | 61.20 | -13.20 | -2 | -2 |
| 2025: Q2 | -0.12 | – | 128 | 64.10 | -4.60 | 12 | 12 |
| 2025: Q3 | 0.05 | – | 133 | 47.20 | 2.20 | 40 | 40 |
| 2025: Q4 | -0.11 | – | 149 | 49.80 | -3.80 | 6 | 6 |
| 2026: Q1 | -13.43 | – | 160 | 43.30 | -494.20 | -229 | -229 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 0 | -3 | -17 | -0.75 | 0 | -10 | 52 |
| 2019 | 0 | -55 | -53 | -2.29 | -39 | 130 | 147 |
| 2020 | 11 | -104 | -103 | -4.09 | -89 | 172 | 241 |
| 2021 | 19 | -173 | -84 | -2.77 | -133 | 120 | 295 |
| 2022 | 77 | -131 | -136 | -3.99 | -120 | 142 | 353 |
| 2023 | 186 | -109 | -163 | -4.00 | -71 | 249 | 647 |
| 2024 | 337 | -88 | -88 | -1.85 | 10 | 226 | 671 |
| 2025 | 521 | -22 | -23 | -0.47 | 56 | 315 | 843 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Mirum Pharmaceuticals, Inc., ein biopharmazeutisches Unternehmen, konzentriert sich auf Entwicklung und Vermarktung neuartiger Therapien für schwerwiegende seltene und Orphan-Erkrankungen.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 418 |
| Headquarters | Foster City, CA |
| Address | 989 East Hillsdale Boulevard, 94404 Foster City, United States |
| Phone | 650 667 4085 |
| Website | mirumpharma.com |
| IPO Date | 18. Jul 2019 |
| ISIN | US6047491013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Christopher Peetz | CEO & Director | 1979 |
| Peter Radovich M.B.A., Ph.D. | COO & President | 1978 |
| Eric H. Bjerkholt M.B.A., M.S. | Chief Financial Officer | 1960 |
| Joanne M. J. Quan M.D. | Chief Medical Officer | 1964 |
| Jean-Luc Girardet Ph.D. | Chief Technical Officer | – |
| Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | – |
| Douglas T. Sheehy J.D. | Chief Legal Officer & Secretary | 1967 |
| Meredith Kiernan | Senior Director of Global Corporate Communications | – |
| Erin Campany | Chief People Officer | 1968 |
| Lara Longpre MBA, MSC | Chief Development Officer | 1970 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 6. Jul 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 1,710 | 124.79 | 213,391 |
| 6. Jul 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 1,975 | 123.74 | 244,387 |
| 6. Jul 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 4,181 | 122.34 | 511,504 |
| 6. Jul 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Sell | 12,134 | 121.65 | 1,476,101 |
| 6. Jul 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | Other | 20,000 | 2.94 | 58,720 |
| 6. Jul 2026 | Bjerkholt Eric | CHIEF FINANCIAL OFFICER | Sell | 300 | 124.94 | 37,482 |
| 6. Jul 2026 | Bjerkholt Eric | CHIEF FINANCIAL OFFICER | Sell | 528 | 123.84 | 65,388 |
| 6. Jul 2026 | Bjerkholt Eric | CHIEF FINANCIAL OFFICER | Sell | 1,048 | 122.43 | 128,307 |
| 6. Jul 2026 | Bjerkholt Eric | CHIEF FINANCIAL OFFICER | Sell | 3,124 | 121.67 | 380,097 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.